SAGE - セ―ジ・セラピュ―ティクス (Sage Therapeutics Inc.) セ―ジ・セラピュ―ティクス

 SAGEのチャート


 SAGEの企業情報

symbol SAGE
会社名 Sage Therapeutics Inc (セ―ジ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 サゲ・セラピューティクス(SAGE Therapeutics Inc.)は臨床段階のバイオ製薬企業である。同社は生命を脅かすまれな中枢神経系(CNS)障害の治療のための治療法の開発・商業化に焦点を当てる。同社の最初の製品候補であるSAGE-547はガンマ - アミノ酪酸 - A(GABAA)受容体のシナプスおよびシナプス調整剤として作用するニューロステロイドであるアロプレグナノロンの静脈内製剤である。同社の次世代製品候補であるSAGE-217およびSAGE-689は、GABA A受容体系を標的とする。同社はCNSシナプスおよびシナプス外受容体の選択的アロステリック調節に基づいて薬物を開発することに焦点を当てる。同社の化学基盤は、GABAAまたはN-メチル-D-アスパラギン酸またはN-メチル-D-アスパラギン酸(NMDA)受容体のアロステリックモジュレータである内因性・化学的に修飾された合成神経活性ステロイド化合物の化学骨格に焦点を当てる。   セ―ジ・セラピュ―ティクスは米国のバイオ医薬品企業。2010年設立。生命を脅かす中枢神経系障害を治療する薬の開発、商品化に焦点を当てる主要プログラムのSAGE-547は、超難治てんかん重積状態の臨床開発中の製品候補。また、AGE-689とSAGE-217もてんかん治療の製品候補。   Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing new pathways with the goal of improving brain health, and its depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Its mission is to make medicines that matter so people can get better, sooner.
本社所在地 215 First Street Cambridge MA 02142 USA
代表者氏名 Kevin P. Starr ケヴィン・P・スター
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-299-8380
設立年月日 40269
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 257人
url www.sagerx.com
nasdaq_url https://www.nasdaq.com/symbol/sage
adr_tso
EBITDA EBITDA(百万ドル) -244.32400
終値(lastsale) 134.75
時価総額(marketcap) 6288013886
時価総額 時価総額(百万ドル) 5707.977
売上高 売上高(百万ドル) 90.00000
企業価値(EV) 企業価値(EV)(百万ドル) 4615.544
当期純利益 当期純利益(百万ドル) -234.71700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 SAGE Therapeutics Inc revenues increased from $0K to $90M. Net loss decreased 28% to $91.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income (expense) net increase from $1.4M to $8.7M (income) Other income (expense) net increase from $25K (expense) to $24K (income).

 SAGEのテクニカル分析


 SAGEのニュース

   Sage Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation  2022/03/01 14:10:46 Seeking Alpha
   Sage Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference  2022/02/28 21:05:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 10:30am ET. A live webcast of the fireside chat can be accessed on the Investor page of Sage’s website at investor.sag
   Sage Therapeutics, Inc. (SAGE) Q4 2021 Earnings Call Transcript  2022/02/25 04:13:58 AlphaStreet
Sage Therapeutics, Inc. (NASDAQ: SAGE) Q4 2021 earnings call dated Feb. 24, 2022 Corporate Participants: Helen Rubinstein — Investor Relations Officer Barry Greene — Chief Executive Officer Jim Doherty — Chief Development Officer Kimi Iguchi — Chief Financial […] The post Sage Therapeutics, Inc. (SAGE) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .
   Sage Therapeutics'' (SAGE) CEO Barry Greene on Q4 2021 Results - Earnings Call Transcript  2022/02/24 19:20:23 Seeking Alpha
   Sage Therapeutics GAAP EPS of -$2.12 beats by $0.05, revenue of $1.6M misses by $0.17M  2022/02/24 11:32:36 Seeking Alpha
Sage Therapeutics press release (SAGE): Q4 GAAP EPS of -$2.12 beats by $0.05.Revenue of $1.6M (-99.9% Y/Y) misses by $0.17M.Ended 2021 with cash balance of $1.7 billion;…
   Rapid-acting Sage Therapeutics and Biogens zuranolone could alter way depression is treated, says GlobalData  2021/06/25 14:50:53 Global Data
Sage Therapeutics and Biogen have recently announced positive results from a pivotal Phase III trial for their novel, GABA A receptor allosteric modulator, antidepressant zuranolone. The post Rapid-acting Sage Therapeutics and Biogens zuranolone could alter way depression is treated, says GlobalData appeared first on GlobalData .
   How Sage Therapeutics Beaten-Down Stock Could Come Back  2021/06/21 14:19:00 Barron''s
Jefferies analyst Andrew Tsai called the stocks swoon last week an overreaction. It should recover within the next three to six months, he said.
   What Happened to Sage Therapeutics Stock?  2021/06/21 10:21:00 The Motley Fool
Sage has been struggling for some time to bring its flagship antidepressant to the market.
   Here''s Why Sage Therapeutics Tanked This Week  2021/06/19 11:00:00 The Motley Fool
The neuroscience-focused biotech company didn''t give investors the result they wanted.
   Sage Therapeutics: Should You Buy This Beaten-Down Stock? Analyst Weighs In  2021/06/18 00:13:38 TipRanks
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only a buck or two

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セ―ジ・セラピュ―ティクス SAGE Sage Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)